Affimed Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
78
- Stock Symbol
-
AFMDQ
- Investments
-
1
Affimed General Information
Description
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
Contact Information
Website
www.affimed.comCorporate Office
- Gottlieb-Daimler-Strasse second
- 68165 Mannheim
- Germany
Corporate Office
- Gottlieb-Daimler-Strasse second
- 68165 Mannheim
- Germany
Affimed Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| 24.3K |
Affimed Financials Summary
As of 30-Sep-2024, Affimed has a trailing 12-month revenue of $951K.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 30,381 | 12,467 | (15,493) | 443,688 |
| Revenue | 951 | 8,954 | 43,479 | 47,725 |
| EBITDA | (72,072) | (111,334) | (85,661) | (65,588) |
| Net Income | (75,879) | (114,633) | (90,425) | (68,009) |
| Total Assets | 44,630 | 107,397 | 215,029 | 254,903 |
| Total Debt | 14,396 | 21,391 | 19,506 | 21,162 |
Affimed Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Affimed Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Affimed Comparisons
Industry
Financing
Details
Affimed Competitors (75)
One of Affimed’s 75 competitors is Immatics, a Formerly VC-backed company based in Tuebingen, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Immatics | Formerly VC-backed | Tuebingen, Germany | ||||
| Celldex | Formerly VC-backed | Hampton, NJ | ||||
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| TME Pharma | Formerly VC-backed | Berlin, Germany | ||||
| Cellectis | Formerly VC-backed | Paris, France |
Affimed Patents
Affimed Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4751734-A1 | Bispecific antibody construct dosage regimen for treating nsclc | Pending | 29-Nov-2024 | ||
| WO-2026115158-A1 | Bispecific antibody construct dosage regimen for treating nsclc | Pending | 29-Nov-2024 | ||
| EP-4751731-A1 | Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a taxane | Pending | 29-Nov-2024 | ||
| WO-2026115137-A1 | Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a taxane | Pending | 29-Nov-2024 | ||
| EP-4751777-A1 | Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a vegfr-2 inhibitor | Pending | 29-Nov-2024 | C07K16/2863 |
Affimed Signals
Affimed Investments (1)
Affimed’s most recent deal was a Later Stage VC with Amphivena Therapeutics for . The deal was made on 26-Jun-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Amphivena Therapeutics | 26-Jun-2017 | Later Stage VC | Biotechnology |
Affimed ESG
Risk Overview
Risk Rating
Updated March, 31, 2023
29.65 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,942
Rank
Percentile
Pharmaceuticals
Industry
of 914
Rank
Percentile
Biotechnology
Subindustry
of 412
Rank
Percentile
Affimed FAQs
-
When was Affimed founded?
Affimed was founded in 2000.
-
Where is Affimed headquartered?
Affimed is headquartered in Mannheim, Germany.
-
What is the size of Affimed?
Affimed has 78 total employees.
-
What industry is Affimed in?
Affimed’s primary industry is Drug Discovery.
-
Is Affimed a private or public company?
Affimed is a Public company.
-
What is Affimed’s stock symbol?
The ticker symbol for Affimed is AFMDQ.
-
What is Affimed’s current revenue?
The trailing twelve month revenue for Affimed is $951K.
-
Who are Affimed’s competitors?
Immatics, Celldex, Agenus, TME Pharma, and Cellectis are some of the 75 competitors of Affimed.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process